Semin Respir Crit Care Med 2000; 21(1): 0019-0032
DOI: 10.1055/s-2000-9927
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

New Antibiotics in Pulmonary and Critical Care Medicine: Focus on Advanced Generation Quinolones and Cephalosporins

Paul G. Ambrose1 , Robert C. Owens, Jr.2
  • 1University of the Pacific, School of Pharmacy Stockton, California, and Kendle International, Inc
  • 2Maine Medical Center, Portland, Maine, and University of Vermont, College of Medicine, Burlington, Vermont
Further Information

Publication History

Publication Date:
31 December 2000 (online)

 

ABSTRACT

The primary goal in the treatment of respiratory tract infections is to provide the best possible clinical outcome for the patients. In order for this to occur, one must consider and synthesize a tremendous amount of data, much of it changing continually. Important considerations include the pharmacokinetics of the selected agent, its microbiological potency when used alone and in combination with various other agents, and the susceptibilities of the target organisms. Gram-negative bacilli remain among the most frequent cause of bacterial infection in the intensive care unit and in debilitated populations. They also have the ability to resist the best therapies. Among the topics to be discussed here are the important pharmacodynamic concepts and their role in the determination of clinical efficacy, the newer quinolone agents, newly emerging mechanisms of resistance, and recent countermeasures that have been added to the therapeutic armamentarium. In addition, specific strategies designed to combat current resistance trends supported by several recent publications will be reviewed.

KEYWORD

Pharmacodynamics - quinolones - cephalosporins

REFERENCES

  • 1 Eagle H, Fleischman R, Levy M. Continuous vs discontinuous therapy with penicillin.  N Engl J Med . 1953;  238 481-488
    PubMedGoogle Scholar
  • 2 Eagle H. Effect of schedule of administration on therapeutic efficacy of penicillin: Importance of aggregate time penicillin remains at effectively bactericidal levels.  Am J Med . 1950;  9 280-299
    CrossrefPubMedGoogle Scholar
  • 3 Eagle H, Fleischman R, Musselman A D. Effective concentrations of penicillin in vitro and in vivo for streptococci and pneumococci, and Trepomena.  J Bacteriol . 1950;  59 625-643
    PubMedGoogle Scholar
  • 4 Craig W A. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.  Diagn Microbiol Infect Dis . 1995;  22 89-96
    CrossrefPubMedGoogle Scholar
  • 5 Nishida M, Murakawa T, Kaminura T. Bactericidal activity of cephalosporins in an in-vitro model simulating serum levels.  Antimicrob Agents Chemother . 1978;  14 6-12
    PubMedGoogle Scholar
  • 6 Moore R D, Lietman P S, Smith C R. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimum inhibitory concentration.  J Infect Dis . 1987;  155 93-99
    CrossrefPubMedGoogle Scholar
  • 7 Prestom S L, Drusano G L, Berman A L. Pharmacodynamics of levofloxacin.  JAMA . 1998;  279 125-129
    CrossrefPubMedGoogle Scholar
  • 8 Fong I W, Cheng P C, Hinton N A. Fungicidal effect of amphotericin B in urine: In vitro study to assess feasibility of bladder washout for localization of site of candiduria.  Antimicrob Agents Chemother . 1991;  35 1856-1859
    PubMedGoogle Scholar
  • 9 Krieger J N, Dickins C S, Rein M F. Use of time-kill technique for susceptibility testing of Trichomonas vaginalis Antimicrob Agents Chemother .  1985;  27 332-336
    PubMedGoogle Scholar
  • 10 Lutsar I, Friedland I R, Wubbel L. Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneucoccal meningitis.  Antimicrob Agents Chemother . 1998;  42 2650-2655
    PubMedGoogle Scholar
  • 11 Forrest A, Nix D E, Ballow C H, Scgentag J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.  Antimicrob Agents Chemother . 1993;  37 1073-1081
    CrossrefPubMedGoogle Scholar
  • 12 Lacy M K, Lu W, Xu X, Nicolau D P, Quintiliani R, Nightingale C H. Pharmacodynamic comparison of levofloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.  Antimicrob Agents Chemother . 1999;  43 672-677
    PubMedGoogle Scholar
  • 13 Vesga O, Craig W A. Activity of levofloxacin against penicillin-resistant streptococcus pnemoniae in normal and neutropenic mice. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, September 15-18, 1996
    Google Scholar
  • 14 Lee B L, Padula A M, Kimbrough R C. Infectious complications with respiratory pathogens despite ciprofloxacin therapy.  N Engl J Med . 1991;  325 520-521
    PubMedGoogle Scholar
  • 15 Owens Jr C J, Ambrose P G, Quintiliani R. Antibiotic protein binding: Therapeutic implications.  Antibiotics for Clinicians . 1997;  1 125-127
    PubMedGoogle Scholar
  • 16 Craig W A, Shu B. Theory and practical impact of binding of antimicrobials to serum proteins and tissue.  Scan J Infect Dis . 1978;  14(suppl) 92-99
    PubMedGoogle Scholar
  • 17 Shyu W C, Quintiliani R, Nightingale C H, Dudley M N. Effect of protein binding on drug penetration into blister fluid.  Antimicrob Agents Chemother . 1988;  32 128-130
    PubMedGoogle Scholar
  • 18 Rolinson G N. The significance of protein binding of antibiotics in bacterial chemotherapy.  J Antimicrob Chemother . 1980;  6 311-317
    PubMedGoogle Scholar
  • 19 Craig W A, Kunin C M. Significance of serum protein and tissue binding of antimicrobial agents.  Annu Rev Med . 1976;  27 287-300
    CrossrefPubMedGoogle Scholar
  • 20 Grew R K, Moellering Jr C R. Effect of protein binding on activity of penicillins in combination with gentimicin against enterococci.  Antimicrob Agents Chemother . 1979;  15 87-92
    PubMedGoogle Scholar
  • 21 Merrikin D J, Briant J, Rolinson G N. Effect of protein binding on antibiotic activity in vivo.  J Antimicrob Chemother . 1983;  11 233-238
    PubMedGoogle Scholar
  • 22 Moody J A, Peterson L R, Gerding D N. Cefoperazone treatment efficacy: Dependant on protein binding 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 17-20, 1985. Abstract 557
    Google Scholar
  • 23 Andriole V T. The quinolones. In: Andriole VT, ed. The Quinolones, 2nd ed San Diego, CA: Academic Press 1998: 417-426
    Google Scholar
  • 24 Stein G E. Pharmacokinetics and dynamics of newer quinolones.  Clin Infect Dis . 1996;  23(suppl 1) S19-24
    CrossrefPubMedGoogle Scholar
  • 25 Raxar package insert. Glaxo Pharmaceutical, November 1997
    Google Scholar
  • 26 Ambrose P G, Owens Jr C R, Quintiliani R, Nightingale C H. New generation quinolones.  Conn Med . 1997;  61 269-272
    PubMedGoogle Scholar
  • 27 Owens Jr C R, Ambrose P G, Quintiliani R, Nightingale C H. Classifying quinolone anti-infective agents by generation: A pharmacodynamic approach to rational drug selection.  Antibiotics for Clinicians . 1997;  1 70-74
    PubMedGoogle Scholar
  • 28 Owens Jr R C, Ambrose P G, Quintiliani R, Nightingale C H. Quinolones classified by generation: A pharmacodynamic analysis of respiratory tract and anaerobic pathogens. 32nd Annual ASHP Midyear Clinical Meeting, Atlanta, Georgia, December 8, 1997
    Google Scholar
  • 29 Domagala J M, Hanna L D, Heifetz C L. New structure-activity relationships of the quinolone antibacterials useing the target enzyme: The development and application of a DNA gyrase assay.  J Med Chem . 1986;  29 394-404
    CrossrefPubMedGoogle Scholar
  • 30 Domagala J M. Structure-activity and structure-side-effect relationshipsfor quinolone antibacterials.  J Antimicrob Chemother . 1994;  33 685-706
    PubMedGoogle Scholar
  • 31 Blum M D, Graham D J, McCloskey C A. Temafloxacin syndrome: Review of 95 cases.  Clin Infect Dis . 1994;  18 946-950
    PubMedGoogle Scholar
  • 32 Levoquin package insert. Ortho Pharmaceutical, December 1996 . 
    Google Scholar
  • 33 Lacreta F, Kollia G, Behr D, Stoltz R, Grasela D. Effect of a high-fat meal on the bioavailability of gatifloxacin in heathly volunteers. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 24-27, 1998
    Google Scholar
  • 34 Schaumann R, Claros M C, Pless B, Rodloff A C. In vitro activity of gatifloxacin against anaerbic bacteria compared with other quinolones and non-quinolone antimicrobials. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 24-27, 1998
    Google Scholar
  • 35 Asahina Y, Ishizaki T, Suzue S. Recent advances in structure activity relationships in new quinolones.  Prog Drug Res . 1992;  38 57-106
    PubMedGoogle Scholar
  • 36 Hecht D W, Wexler H M. In vitro susceptability of anaerobes to quinolones in the United States.  Clin Infect Dis . 1996;  23(suppl 1) S2-S8
    PubMedGoogle Scholar
  • 37 Peterson M L, Hovde L B, Wright D H, Hoang A D, Rotschafer J C. Trovafloxacin and levofloxacin resistance in Bacteroides fragilis 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 24-27, 1998. Abstract E-32
    Google Scholar
  • 38 Matsumoto M, Kojima K, Nagano H, Matsubara S, Yokata T. Photostability and biological activity of fluoroquinolones substituted at the 8 position after UV irradiation.  Antimicrob Agents Chemother . 1992;  36 1715-1719
    PubMedGoogle Scholar
  • 39 Vohr H W, Wasinska G, Ahr H J. Studies on the phatotoxic potential of BAY 12-8039. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996. Abstract F021
    Google Scholar
  • 40 Kusajima H, Manita S, Yamamoto T, Hosaka M, Momo K. Phototoxicity and photochemical generation of reactive oxygen by new quinolones. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998. Abstract A-76
    Google Scholar
  • 41 Ferguson J, Mcewen J, Goehler K, Mignot A. A double-blind, placebo- and positive-controlled, randomized study to investigate the phototoxic potential of gatifloxacin, a new fluoroquinolone antibiotic. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998. Abstract A-78
    Google Scholar
  • 42 Hentge D J. Human Intestinal Microflora in Health and Disease.  New York: Academic Press 1993
    Google Scholar
  • 43 Soleim H A, Scheline R R. Metabolism of xenobiotics by strains of intestinal bacteria.  Acta Pharmacol Toxicol . 1972;  31 471
    PubMedGoogle Scholar
  • 44 Mathan V I, Wiederman J, Dobkin J F. Geographic differences in digoxin inactivation, a metabolic activity of the human anaerobic gut flora.  Gut . 1989;  30 971-977
    PubMedGoogle Scholar
  • 45 Lindenbaum J, Rund D G, Butler Jr P V. Inactivation of digoxin by the gut flora: Reversal by antibiotic therapy.  N Engl J Med . 1970;  42 341-345
    PubMedGoogle Scholar
  • 46 Kromer W. Endogenous and exogenous opioids in the control of gastroimtestinal motility and secretion.  Pharmacol Rev . 1988;  40 121-162
    PubMedGoogle Scholar
  • 47 Coupar I M. Opioid action on the intestine: the importance of the intestinal mucosa.  Life Sci . 1987;  41 917-925
    CrossrefPubMedGoogle Scholar
  • 48 Trovan package insert. Pfizer Pharmaceuticals, January 1997 . 
    Google Scholar
  • 49 Morrow C, McArole C, Pettitt L. Brief report: Pharmacokinetics of orally administered ciprofloxacin in abdominal surgery.  Am J Med . 1989;  87(suppl 5A) 86-88
    CrossrefPubMedGoogle Scholar
  • 50 Mizuki Y, Fujiwari I, Yamaguchi T. Pharmcokinetic interations related to the chemical structures of fluoroquinolones.  J Antimicrob Chemother . 1996;  37(suppl A) 41-55
    PubMedGoogle Scholar
  • 51 Sanders C C, Sanders Jr E W. Emergence of resistance to cefamandole: Possible role of cefoxitin-inducible β-lactamases.  Antimicrob Agents Chemother . 1979;  15 792-797
    PubMedGoogle Scholar
  • 52 Meideiros A A. Evolution and dessemination of beta-lactamases excellocted by generations of beta-lactam antibiotics.  Clin Infec Dis . 1997;  24(suppl 1) 19-45
    PubMedGoogle Scholar
  • 53 Knothe H, Shah P, Kremery V. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens Infection .  1983;  11 315-317
    CrossrefPubMedGoogle Scholar
  • 54 Rahal J J, Urban C, Horn D. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella JAMA .  1998;  280 1233-1237
    PubMedGoogle Scholar
  • 55 Burke J P. Antibiotic resistance-Squeezing the balloon?.  JAMA . 1998;  280 1270-1271
    CrossrefPubMedGoogle Scholar
  • 56 Paterson D L, Ko W, Von Gottberg A. In vitro susceptibility and clinical outcome of bacteremia due to extended-spectrum beta-lactamase (ESBL) producing Klebsiella pneumoniae Clin Infect Dis .  1998;  27 956
    PubMedGoogle Scholar
  • 57 Pfaller M A, Jones R N, Doern G V. Bacterial pathogens from patients with bloodstream infections: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997).  Antimicrob Agents Chemother . 1998;  42 1762-1770
    PubMedGoogle Scholar
  • 58 Jones R N, Pfaller M A, Doern G V. Antimicrobial activity and spectrum investigation of eight broad-spectrum β-lactam drugs: A 1997 surveillance trial in 102 medical centers in the united states.  Diagn Microbiol Infect Dis . 1997;  30 215-228
    PubMedGoogle Scholar
  • 59 Jones R N, Marshall S A. Antimicrobial activity of cefepime tested against class C β-lactamase-producing strains resistant to ceftazidime: A multilaboratory national and international clinical isolate study.  Diagn Microbiol Infect Dis . 1994;  19 33-38
    CrossrefPubMedGoogle Scholar
  • 60 Thornsberry C, Ogilvie P, Kahn J. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season.  Diagn Microbiol Infect Dis . 1997;  29 249-257
    CrossrefPubMedGoogle Scholar
  • 61 Sanders C C, Sanders Jr E W. Emergence of resistance during therapy with the newer β-lactam antibiotics: Role of inducible β-lactamases and implications for the future.  Rev Infect Dis . 1983;  5 639-648
    PubMedGoogle Scholar
  • 62 Sanders C C, Sanders Jr E W. β-lactam resistance in gram-negative bacteria: Global trends and clinical impact.  Clin Infect Dis . 1992;  15 824-839
    PubMedGoogle Scholar
  • 63 Johnson M P, Ramphal R. β-lactam resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy.  J Infect Dis . 1990;  162 981-983
    PubMedGoogle Scholar
  • 64 Fussle R, Biscoping J, Behr R. Development of resistance by Enterobacter cloacae during therapy of pulmonary infections in intensive care patients.  Clin Invest . 1994;  72 1015-1019
    PubMedGoogle Scholar
  • 65 Burwen D R, Banerjee S N, Gaynes R P. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States.  J Infect Dis . 1994;  170 1622-1625
    PubMedGoogle Scholar
  • 66 Quinn J P. Clinical problems posed by multiresistant nonfermenting gram-negative pathogens.  Clin Infect Dis . 1998;  27(suppl 1) s117-s124
    PubMedGoogle Scholar
  • 67 Ambrose P G, Richerson M A, Bui K. Cost-effectiveness analysis of cefepime versus ceftazidime in ICU patients with hospital-acquired pneumonia.  Clin Infect Dis . 1998;  27 1046
    PubMedGoogle Scholar
  • 68 Chow J W, Fine M J, Shlaes D M. Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy.  Ann Intern Med . 1991;  115 585-590
    CrossrefPubMedGoogle Scholar
  • 69 Sanders Jr E W, Sanders C C. Enterobacter spp.: Pathogens poised to fluorish at the turn of the century.  Clin Micro Rev . 1997;  10 220-241
    PubMedGoogle Scholar
  • 70 Holmberg S D, Solomon S L, Blake P A. Health and economic impacts of antimicrobial resistance.  Rev Infect Dis . 1987;  9 1065-1078
    PubMedGoogle Scholar
  • 71 Aronoff S C, Shlaes D M. Factors that influence the evolution of β-lactam resistance in β-lactamase-inducible strains of Enterobacter cloacae and Pseudomonas aeruginosa J Infect Dis .  1987;  155 936-941
    PubMedGoogle Scholar
  • 72 Drusano G L, Craig W A. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections.  J Chemother . 1997;  9(suppl 3) 936-941
    PubMedGoogle Scholar
  • 73 Thomas J K, Forrest A, Bhavnani S M. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy.  Antimicrob Agents Chemother . 1998;  42 521-527
    PubMedGoogle Scholar
  • 74 Sanders Jr E W, Tenney J H, Kessler R E. Efficacy of cefepime in the treatment of infections due to multiply resistant enterobacter species.  Clin Infect Dis . 1996;  23 454-461
    PubMedGoogle Scholar
  • 75 Chow A W, Wong J, Bartlett K H. Synergistic interactions of ciprofloxacin and extended-spectrum β-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophilia Antimicrob Agents Chemother .  1988;  32 782-784
    PubMedGoogle Scholar
  • 76 Cometta A, Baumgartner J D, Lew D. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients.  Antimicrob Agents Chemother . 1994;  38 1309-1313
    CrossrefPubMedGoogle Scholar
  • 77 Korvick J A, Bryan C S, Farber B. Prospective observational study of klebsiella bacteremia in 230 patients: Outcome for antibiotic combinations versus monotherapy.  Antimicrob Agents Chemother . 1992;  36 2639-2644
    CrossrefPubMedGoogle Scholar
  • 78 Leibovici L, Paul M, Poznanski O. Monotherapy versus β-lactam-aminoglycoside combination treatment for gram-negative bacteremia: A prospective, observational study.  Antimicrob Agents Chemother . 1997;  41 1127-1133
    CrossrefPubMedGoogle Scholar
  • 79 Neu H C. Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.  Drugs . 1993;  45(suppl 3) 54-58
    CrossrefPubMedGoogle Scholar
  • 80 Stratton C W, Franke J J, Weeks L S. Comparison of the bactericidal activity of ciprofloxacin alone and in combination with selected antipseudomonal β-lactam agents against clinical isolates of Pseudomonas aeruginosa Diagn Microbiol Infect Dis .  1989;  11 41-52
    PubMedGoogle Scholar
  • 81 Eliopoulos G M, Eliopoulos C T. Ciprofloxacin in combination with other antimicrobials.  Am J Med . 1989;  87(suppl 5A) 17s-22s
    PubMedGoogle Scholar
  • 82 Tolzis P, Yamashita T, Vilt L. Antibiotic resistance does not alter endemic colonization with resistant gram-negative rods in a pediatric intensive care unit.  Crit Care Med . 1998;  26 1893-1896
    PubMedGoogle Scholar
  • 83 Goldman M, Adelman M H, Thompson C E. Impact of conversion from ceftazidime to cefepime on ICU resistance patterns of Enterobacter cloacae 8th International Congress of Infectious Diseases, Boston, Massachusetts, May 1998 . 
    Google Scholar
  • 84 Mebis J, Gossens H, Meeus I. Decreasing antibiotic resistance of inducible Enterobacteriaceae by introducing combination therapy.  Blood . 1996;  88 505a
    PubMedGoogle Scholar
  • 85 Owens Jr R C, Owens C A, Holloway W J. Comparative evaluation of a cefepime Q12-hour dosing schedule as empiric monotherapy infebril neutropenic patients.  Pharmaco Ther . 1999;  19 496-497
    PubMedGoogle Scholar
      >